Efficacy and Safety of Polymer-Free Ultrathin Strut Sirolimus-Probucol Coated Drug-Eluting Stents for Chronic Total Occlusions: Insights from the Coroflex ISAR 2000 Worldwide Registry

Table 3

Periprocedural drug therapy.

Drug type		Drug	Patients, n (%)	<25 mm lesion length, n (%)	≥25 mm lesion length, n (%)	value
Pre-PCI	Antiplatelet therapy (APT)	Clopidogrel	59 (53.9%)	29 (59.2%)	30 (48.4%)	0.391
		Prasugrel	18 (16.2%)	7 (14.3%)	11 (17.7%)
		Ticagrelor	12 (10.8%)	7 (14.3%)	5 (8.1%)
		Ticlopidine	1 (0.9%)	0 (0.0%)	1 (1.6%)
		Aspirin only	10 (9.0%)	2 (4.1%)	8 (12.9%)
		No preloading	11 (9.9%)	4 (8.2%)	7 (11.3%)
	Oral anticoagulation (OAC)	All OAC	1 (0.9%)	1 (2.0%)	0 (0.0%)	0.258
		Vitamin K antagonist (VKA)	0 (0.0%)	0 (0.0%)	0 (0.0%)	0.258
		New oral anticoagulation (NOAC)	1 (0.9%)	1 (2.0%)	0 (0.0%)
Post-PCI	Antiplatelet therapy (APT)	Clopidogrel	92 (82.9%)	40 (81.6%)	52 (83.9%)	0.167
		Prasugrel	4 (3.6%)	0 (0.0%)	4 (6.5%)
		Ticagrelor	12 (10.8%)	4 (16.3%)	4 (6.5%)
		Aspirin only	1 (0.9%)	0 (0.0%)	1 (0.9%)
		Unknown	2 (1.8%)	1 (2.0%)	1 (0.9%)